1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-1.59
Negative P/E while Biotechnology median is -1.81. Seth Klarman would scrutinize path to profitability versus peers.
No Data
No Data available this quarter, please select a different quarter.
2.30
P/B 50-90% of Biotechnology median of 3.44. Mohnish Pabrai would examine if this discount presents opportunity.
-8.10
Negative FCF while Biotechnology median P/FCF is -9.17. Seth Klarman would investigate cash flow improvement potential.
-8.10
Negative operating cash flow while Biotechnology median P/OCF is -9.20. Seth Klarman would investigate operational improvement potential.
2.30
Fair value ratio 50-90% of Biotechnology median of 3.44. Mohnish Pabrai would examine if this gap presents opportunity.
-15.75%
Negative earnings while Biotechnology median yield is -7.58%. Seth Klarman would investigate path to profitability.
-12.35%
Negative FCF while Biotechnology median yield is -5.82%. Seth Klarman would investigate cash flow improvement potential.